North Contraction of the second secon


Examining Heart Failure Management: How Can We Do Better?

CHAMP-HF Registry

- 3,518 patients with HFrEF
- 150 United States primary care and cardiology clinics

Greene SJ, Butler J, Albert NM, et al. J Am Coll Cardiol. 2018;72(4):351-366.

CHAMP-HF Registry: Use of GDMT



Adapted from: Greene SJ, Butler J, Albert NM, et al. J Am Coll Cardiol. 2018;72(4):351-366.

CHAMP-HF Registry (con't.)

- Among eligible registry patients
 - 22.1% were simultaneously prescribed ACEi/ARB/ARNi, beta-blocker, and MRA therapy
 - Only 1.1% were prescribed target doses of all 3 therapies

Greene SJ, Butler J, Albert NM, et al. J Am Coll Cardiol. 2018;72(4):351-366.

European Data: Use of GDMT

- Swedish Heart Failure Registry
 - 11,215 patients with HFrEF <40%
 - 40% received an MRA

BIOSTAT-CHF

 Higher baseline K⁺ was an independent predictor of lower ACEi/ARB dosages (OR 0.70; 95% CI 0.51–0.98)

GDMT = guideline-directed medical therapy Savarese G, Carrero JJ, Pitt B, et al. *Eur J Heart Fail*. 2018;20(9):1326-1334. eusekamp JC, Tromp J, van der Wal HH, et al. *Eur J Heart Fail*. 2018;20(5):923-930.

Heart Failure Team Care

- Engage the patient as a team member
- Evaluate the low-hanging fruits of:
 - Low sodium diet
 - Exercise
 - Smoking cessation
 - Adherence to medications
- Pharmacists can review medication side effect profiles
- Nutritionists can discuss diet recommendations

Heart Failure Team Care (con't.)

• Treatment of comorbidities

- High blood pressure
- Diabetes
- Obesity
- Dyslipidemia
- Iron deficiency

ESC Expert Consensus

Potassium binders should facilitate the use of RAASi therapy.

RAASi = renin-angiotensin-aldosterone inhibitor Rosano GMC, Tamargo J, Kjeldsen KP, et al. *Eur Heart J Cardiovasc Pharmacother*. 2018;4(3):180-188.

Evaluation Other Medications as a Cause of Hyperkalemia


- NSAIDs
- Antibiotics
- Antifungal therapies
- Nutraceuticals, supplements

HF-ACTION

- Exercise is safe in HFrEF
- May decrease risk of HF hospitalization or CV death


O'Connor CM, Whellan DJ, Lee KL, et al. JAMA. 2009;301(14):1439-1450.

Iron Deficiency Reduces Exercise Capacity in CHF



Adapted from: Jankowska EA, Rozentryt P, Witkowska A, et al. J Card Fail. 2011;17(11):899-906.

CONFIRM-HF: IV Iron Improves Exercise Capacity in HFrEF



ESC HF Guidelines

- Test serum ferritin and TSAT in newly diagnosed patients
- Iron deficiency defined as
 - Ferritin <100 μ g/L or
 - Ferritin 100-299 μ g/L with TSAT <20%

Ponikowski P, Voors AA, Anker SD, et al. Eur J Heart Fail. 2016;18(8):891-975.

Iron Supplementation

- Oral iron has no effect on exercise capacity
- Only IV iron improves
 - Exercise capacity
 - Quality of life

ACC/AHA/HFSA Guidelines

- Patients with NYHA class II and III HF and iron deficiency may benefit from IV iron replacement (Class IIb)
- Iron deficiency defined as
 - Ferritin <100 ng/mL or
 - Ferritin 100-300 ng/mL with TSAT <20%

Yancy CW, Jessup M, Bozkurt B, et al. J Am Coll Cardiol. 2017;70(6):776-803.

Stability is an Illusion

- Follow the guidelines
- Titrate doses to achieve optimal GDMT
- Consider:
 - Potassium binders
 - IV iron
- More education about food and diet